Attitudes  ||| S:0 E:10 ||| NNS
of  ||| S:10 E:13 ||| IN
patients  ||| S:13 E:22 ||| NNS
and  ||| S:22 E:26 ||| CC
mental  ||| S:26 E:33 ||| JJ
health  ||| S:33 E:40 ||| NN
staff  ||| S:40 E:46 ||| NN
to  ||| S:46 E:49 ||| TO
antipsychotic  ||| S:49 E:63 ||| VB
long-acting  ||| S:63 E:75 ||| JJ
injections ||| S:75 E:85 ||| NNS
:  ||| S:85 E:87 ||| :
systematic  ||| S:87 E:98 ||| RB
review  ||| S:98 E:105 ||| VB
The  ||| S:105 E:109 ||| DT
attitudes  ||| S:109 E:119 ||| NNS
of  ||| S:119 E:122 ||| IN
staff  ||| S:122 E:128 ||| NN
and  ||| S:128 E:132 ||| CC
patients  ||| S:132 E:141 ||| NNS
have  ||| S:141 E:146 ||| VBP
been  ||| S:146 E:151 ||| VBN
demonstrated  ||| S:151 E:164 ||| VBN
to  ||| S:164 E:167 ||| TO
influence  ||| S:167 E:177 ||| VB
the  ||| S:177 E:181 ||| DT
acceptance  ||| S:181 E:192 ||| NN
of  ||| S:192 E:195 ||| IN
long-acting  ||| S:195 E:207 ||| JJ
injections  ||| S:207 E:218 ||| NNS
( ||| S:218 E:219 ||| -LRB-
LAIs ||| S:219 E:223 ||| NNP
)  ||| S:223 E:225 ||| -RRB-
or  ||| S:225 E:228 ||| CC
depot  ||| S:228 E:234 ||| JJ
antipsychotics ||| S:234 E:248 ||| NN
.  ||| S:248 E:250 ||| .
To  ||| S:250 E:253 ||| TO
examine  ||| S:253 E:261 ||| VB
the  ||| S:261 E:265 ||| DT
attitudes  ||| S:265 E:275 ||| NNS
of  ||| S:275 E:278 ||| IN
patients  ||| S:278 E:287 ||| NNS
and  ||| S:287 E:291 ||| CC
staff  ||| S:291 E:297 ||| NN
to  ||| S:297 E:300 ||| TO
LAIs ||| S:300 E:304 ||| JJ
.  ||| S:304 E:306 ||| .
A  ||| S:306 E:308 ||| DT
systematic  ||| S:308 E:319 ||| JJ
review  ||| S:319 E:326 ||| NN
was  ||| S:326 E:330 ||| VBD
carried  ||| S:330 E:338 ||| VBN
out ||| S:338 E:341 ||| RP
.  ||| S:341 E:343 ||| .
Studies  ||| S:343 E:351 ||| NNS
included  ||| S:351 E:360 ||| VBD
contained  ||| S:360 E:370 ||| VBN
quantitative  ||| S:370 E:383 ||| JJ
data  ||| S:383 E:388 ||| NNS
for  ||| S:388 E:392 ||| IN
attitudes  ||| S:392 E:402 ||| NNS
of  ||| S:402 E:405 ||| IN
patients  ||| S:405 E:414 ||| NNS
or  ||| S:414 E:417 ||| CC
staff  ||| S:417 E:423 ||| NN
to  ||| S:423 E:426 ||| TO
LAIs ||| S:426 E:430 ||| JJ
.  ||| S:430 E:432 ||| .
Twelve  ||| S:432 E:439 ||| CD
studies  ||| S:439 E:447 ||| NNS
published  ||| S:447 E:457 ||| VBN
subsequent  ||| S:457 E:468 ||| JJ
to  ||| S:468 E:471 ||| TO
the  ||| S:471 E:475 ||| DT
systematic  ||| S:475 E:486 ||| JJ
review  ||| S:486 E:493 ||| NN
reported  ||| S:493 E:502 ||| VBD
in  ||| S:502 E:505 ||| IN
2001  ||| S:505 E:510 ||| CD
were  ||| S:510 E:515 ||| VBD
identified ||| S:515 E:525 ||| VBN
.  ||| S:525 E:527 ||| .
Five  ||| S:527 E:532 ||| CD
studies  ||| S:532 E:540 ||| NNS
conveyed  ||| S:540 E:549 ||| VBD
an  ||| S:549 E:552 ||| DT
overall  ||| S:552 E:560 ||| JJ
positive  ||| S:560 E:569 ||| JJ
attitude ||| S:569 E:577 ||| NN
.  ||| S:577 E:579 ||| .
The  ||| S:579 E:583 ||| DT
most  ||| S:583 E:588 ||| RBS
positive  ||| S:588 E:597 ||| JJ
attitudes  ||| S:597 E:607 ||| NNS
among  ||| S:607 E:613 ||| IN
patients  ||| S:613 E:622 ||| NNS
were  ||| S:622 E:627 ||| VBD
seen  ||| S:627 E:632 ||| VBN
in  ||| S:632 E:635 ||| IN
those  ||| S:635 E:641 ||| DT
already  ||| S:641 E:649 ||| RB
prescribed  ||| S:649 E:660 ||| VBN
an  ||| S:660 E:663 ||| DT
LAI ||| S:663 E:666 ||| NNP
.  ||| S:666 E:668 ||| .
Positive  ||| S:668 E:677 ||| JJ
attitudes  ||| S:677 E:687 ||| NNS
of  ||| S:687 E:690 ||| IN
staff  ||| S:690 E:696 ||| NN
correlated  ||| S:696 E:707 ||| VBZ
closely  ||| S:707 E:715 ||| RB
with  ||| S:715 E:720 ||| IN
the  ||| S:720 E:724 ||| DT
extent  ||| S:724 E:731 ||| NN
of  ||| S:731 E:734 ||| IN
their  ||| S:734 E:740 ||| PRP$
knowledge  ||| S:740 E:750 ||| NN
of  ||| S:750 E:753 ||| IN
LAIs ||| S:753 E:757 ||| JJ
.  ||| S:757 E:759 ||| .
Long-acting  ||| S:759 E:771 ||| JJ
injections  ||| S:771 E:782 ||| NNS
continue  ||| S:782 E:791 ||| VBP
to  ||| S:791 E:794 ||| TO
have  ||| S:794 E:799 ||| VB
an  ||| S:799 E:802 ||| DT
image  ||| S:802 E:808 ||| NN
problem ||| S:808 E:815 ||| NN
,  ||| S:815 E:817 ||| ,
arguably  ||| S:817 E:826 ||| RB
perpetuated  ||| S:826 E:838 ||| VBN
by  ||| S:838 E:841 ||| IN
manufacturers  ||| S:841 E:855 ||| NNS
of  ||| S:855 E:858 ||| IN
oral  ||| S:858 E:863 ||| JJ
second-generation  ||| S:863 E:881 ||| JJ
antipsychotic  ||| S:881 E:895 ||| JJ
drugs ||| S:895 E:900 ||| NNS
,  ||| S:900 E:902 ||| ,
and  ||| S:902 E:906 ||| CC
exacerbated  ||| S:906 E:918 ||| VBN
by  ||| S:918 E:921 ||| IN
the  ||| S:921 E:925 ||| DT
predominant  ||| S:925 E:937 ||| JJ
use  ||| S:937 E:941 ||| NN
of  ||| S:941 E:944 ||| IN
these  ||| S:944 E:950 ||| DT
medications  ||| S:950 E:962 ||| NN
as  ||| S:962 E:965 ||| IN
a  ||| S:965 E:967 ||| DT
; ||| S:967 E:968 ||| :
last  ||| S:968 E:973 ||| JJ
resort ||| S:973 E:979 ||| NN
'  ||| S:979 E:981 ||| POS
often  ||| S:981 E:987 ||| RB
for  ||| S:987 E:991 ||| IN
the  ||| S:991 E:995 ||| DT
most  ||| S:995 E:1000 ||| RBS
stigmatized  ||| S:1000 E:1012 ||| JJ
individuals ||| S:1012 E:1023 ||| NNS
.  ||| S:1023 E:1025 ||| .
The  ||| S:1025 E:1029 ||| DT
introduction  ||| S:1029 E:1042 ||| NN
of  ||| S:1042 E:1045 ||| IN
better-tolerated  ||| S:1045 E:1062 ||| JJ
LAIs  ||| S:1062 E:1067 ||| JJ
and  ||| S:1067 E:1071 ||| CC
better  ||| S:1071 E:1078 ||| JJR
education  ||| S:1078 E:1088 ||| NN
of  ||| S:1088 E:1091 ||| IN
both  ||| S:1091 E:1096 ||| DT
staff  ||| S:1096 E:1102 ||| NN
and  ||| S:1102 E:1106 ||| CC
patients  ||| S:1106 E:1115 ||| NNS
may  ||| S:1115 E:1119 ||| MD
encourage  ||| S:1119 E:1129 ||| VB
individuals  ||| S:1129 E:1141 ||| NNS
to  ||| S:1141 E:1144 ||| TO
re-examine  ||| S:1144 E:1155 ||| VB
their  ||| S:1155 E:1161 ||| PRP$
attitudes ||| S:1161 E:1170 ||| NNS
.  ||| S:1170 E:1172 ||| .
